Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Basit Öğe Kaydı
dc.authorid0000-0002-8892-0439
dc.authorscopusid29067508300
dc.authorscopusid55365316700
dc.authorwosidAlbayrak, Yakup/ABA-7651-2020
dc.authorwosidHashimoto, Kenji/I-5800-2015
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorHashimoto, Kenji
dc.date.accessioned2022-05-11T14:41:03Z
dc.date.available2022-05-11T14:41:03Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractFluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
dc.identifier.doi10.4306/pi.2013.10.4.417
dc.identifier.endpage420
dc.identifier.issn1738-3684
dc.identifier.issn1976-3026
dc.identifier.issue4en_US
dc.identifier.pmid24474992
dc.identifier.scopus2-s2.0-84892550172
dc.identifier.scopusqualityQ2
dc.identifier.startpage417
dc.identifier.urihttps://doi.org/10.4306/pi.2013.10.4.417
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9040
dc.identifier.volume10
dc.identifier.wosWOS:000329599900015
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAlbayrak, Yakup
dc.language.isoen
dc.publisherKorean Neuropsychiatric Assoc
dc.relation.ispartofPsychiatry Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSigma receptor
dc.subjectFluvoxamine
dc.subjectAkathisia
dc.subjectDyskinesia
dc.subjectInduced Movement-Disorders
dc.subjectNeuropsychiatric Disorders
dc.subjectReceptor Ligands
dc.subjectTomography
dc.subjectChaperone
dc.subjectDopamine
dc.subjectStress
dc.subjectBrain
dc.subjectDrugs
dc.titleBenefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9040.pdf
Boyut:
226.22 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu